Usually, a doctor watches over the intravenous administration of the injection
others require more intentional behavioral change
Methodology: Data from 200 patients was examined with the intention of identifying those who would be suitable candidates for weight loss treatment with a GLP-1 agonist
N Engl J Med 381:19952008 Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Brueckmann M, Jamal W, Kimura K, Schnee J, Zeller C, Cotton D, Bocchi E, Bhm M, Choi DJ, Chopra V, Chuquiure E, Giannetti N, Janssens S, Zhang J, Gonzalez Juanatey JR, Kaul S, Brunner-La Rocca HP, Merkely B, Nicholls SJ, Perrone S, Pina I, Ponikowski P, Sattar N, Senni M, Seronde MF, Spinar J, Squire I, Taddei S, Wanner C, Zannad F (2020) EMPEROR-Reduced Trial Investigators
Detailed methods are provided in Supplementary Information
The GLP-1 boom is far from overhere's what you need to know May 1st, 2025 Glucagon-like peptide-1 (GLP-1) drugs have made an impact on the market and culture at large at a scale rarely seen since the introduction of the birth control pill